NEW YORK--(BUSINESS WIRE)--
Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, will be presented during a poster session at the American Society of Hematology (ASH) 65th Annual Meeting taking place virtually and in San Diego, California, December 9-12, 2023.
Presentation of SGR-1505 data will include further characterization in preclinical oncology models as well as preliminary clinical biomarker information from the Phase 1 study in healthy subjects, which is nearing completion. The data support continued development of SGR-1505 as a potential therapy for patients with advanced B-cell malignancies, and a Phase 1 dose-escalation study in this patient population is ongoing.
Additionally, data will be presented for SGR-2921 demonstrating strong anti-leukemic activity in preclinical models of acute myeloid leukemia (AML) representing difficult-to-treat disease. CDC7 is a cell cycle kinase in the DNA damage-response pathway and has emerged as a promising therapeutic target in oncology, including for the treatment of AML. Schrödinger recently initiated a Phase 1 dose-escalation study of SGR-2921 designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and recommended dose of SGR-2921 in patients with AML or myelodysplastic syndrome.
Details of the data presentations are as follows:
Title: SGR-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile
Abstract number: 2997
Date & time: Sunday, December 10, 6:00 p.m. - 8:00 p.m. PDT
Location: San Diego Convention Center, Halls G-H
Title: SGR-2921, a Potent CDC7 Inhibitor, Demonstrates Significant Anti-Leukemic Responses in Patient-Derived AML Models Representing Difficult-to-Treat Disease
Abstract number: 2801
Date & time: Sunday, December 10, 6:00 p.m. - 8:00 p.m. PDT
Location: San Diego Convention Center, Halls G-H
Additionally, the following clinical trial-in–progress posters will be presented for both SGR-1505 and SGR-2921:
Title: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of SGR-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies
Abstract number: 3102
Date & time: Sunday, December 10, 6:00 p.m. - 8:00 p.m. PDT
Location: San Diego Convention Center, Halls G-H
Title: A First-in-Human, Phase 1, Dose Escalation Study of SGR-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Abstract number: 1548
Date & time: Saturday, December 9, 5:30 P.M. - 7:30 P.M. PDT
Location: San Diego Convention Center, Halls G-H
Schrödinger will review these data as part of its Pipeline Day, taking place virtually and in person on December 14, 2023. The company’s Pipeline Day will be a hybrid event, with limited in-person attendance available to members of the investment community, and a simultaneous webcast will be available for individual investors and other interested parties who wish to join virtually. The live presentation can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days. To participate in the live webcast, please register for the event . It is recommended that participants register at least 15 minutes in advance of the event.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.
Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit , follow us on and , or visit our blog, .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding the potential advantages of Schrödinger’s computational platform, the clinical potential and favorable properties of its product candidates, including SGR-1505 and SGR-2921, the potential for SGR-1505 to be used for the treatment of advanced B-cell malignancies, the potential for SGR-2921 to be used for the treatment of AML or myelodysplastic syndrome, and the timing, progress, and results of clinical trials for its product candidates. Statements including words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals and the ability to retain and hire key personnel on its business and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023, filed with the Securities and Exchange Commission on November 1, 2023, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.
View source version on businesswire.com:
